KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici | Healthcare M&A Deal

Chiesi Farmaceutici has acquired KalVista Pharmaceuticals, a pharmacy business in Delaware, for $27.00 per share in cash. KalVista Pharmaceuticals develops specialty medicines, and Chiesi Farmaceutici acquisitions expand its healthcare M&A footprint in the pharmacy sector. The strategic acquisition is structured as a merger acquisition through Skyline Merger Sub, a wholly owned subsidiary of Chiesi Farmaceutici, to acquire all outstanding shares of KalVista Pharmaceuticals, Inc. Chiesi Farmaceutici acquisitions are valued at about $49 million and are being pursued as a strategic acquisition to strengthen the buyer’s pipeline and therapeutic capabilities. The tender offer is being initiated under a Schedule TO filing tied to an Agreement and Plan of Merger dated April 28, 2026.